PZ0006
依西美坦
≥98% (HPLC)
别名:
6-Methyleneandrosta-1,4-diene-3,17-dione
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C20H24O2
化学文摘社编号:
分子量:
296.40
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
51111800
MDL number:
Quality Level
assay
≥98% (HPLC)
form
powder
optical activity
[α]/D +250 to +300°, c = 1 in methanol
color
white to off-white
solubility
DMSO: ≥20 mg/mL
storage temp.
2-8°C
SMILES string
C[C@]12CC[C@H]3[C@@H](CC(=C)C4=CC(=O)C=C[C@]34C)[C@@H]1CCC2=O
InChI
1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3/t14-,15-,16-,19+,20-/m0/s1
InChI key
BFYIZQONLCFLEV-DAELLWKTSA-N
Gene Information
human ... CYP19A1(1588)
Biochem/physiol Actions
Exemestane is a steroidal antiestrogen and irreversible aromatase inhibitor. Exemestane acts as a false substrate for the aromatase enzyme. Exemestane also prevents the conversion of androgens to estrogens and is used to treat estrogen-dependent breast cancer.
Exemestane is a steroidal antiestrogen; aromatase inhibitor.
Features and Benefits
This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
Still not finding the right product?
Explore all of our products under 依西美坦
signalword
Danger
hcodes
Hazard Classifications
Aquatic Chronic 2 - Repr. 1B
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
涉药品监管产品
此项目有
Anneleen Lintermans et al.
Expert opinion on drug safety, 10(3), 473-487 (2011-03-25)
Hormone-dependent breast cancer can be successfully treated by either blocking the estrogen receptor, as with tamoxifen, or reducing the production of estrogens, as with aromatase inhibitors. Exemestane is a third-generation aromatase inhibitor used in the treatment of estrogen-receptor-positive breast cancer
Michael Gnant et al.
Journal of the National Cancer Institute, 105(9), 654-663 (2013-02-22)
Breast Cancer Trials of Oral Everolimus 2 (BOLERO-2), a phase III study in postmenopausal women with estrogen receptor-positive breast cancer progressing despite nonsteroidal aromatase inhibitor therapy, showed statistically significant benefits with adding everolimus to exemestane. Moreover, in preclinical studies, mammalian
Duveken B Y Fontein et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(18), 2257-2264 (2013-04-24)
Specific adverse events (AEs) associated with endocrine therapy and related to depletion or blocking of circulating estrogens may be related to treatment efficacy. We investigated the relationship between survival outcomes and specific AEs including vasomotor symptoms (VMSs), musculoskeletal adverse events
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| PZ0006-25MG | 04061832867588 |
| PZ0006-5MG | 04061836687267 |